Nutriband Inc. (NASDAQ: NTRB) Advances Abuse Deterrent Tech Addressing Fentanyl Epidemic
- Fentanyl is a potent opioid that is associated with a significant risk of abuse and overdose, contributing to a major drug crisis in the United States
- Fentanyl has legitimate medical uses in managing severe and chronic pain in medical settings such as hospitals and surgical procedures
- NTRB is advancing its AVERSA(TM) technology that incorporates aversive agents to prevent abuse, diversion, misuse, and accidental exposure to opioids and other drugs with abuse potential
- NTRB was recently granted a patent for AVERSA(TM), strengthening its intellectual property portfolio in the United States and globally across 45 countries
Fentanyl, a potent opioid, poses a significant problem due to its potential for abuse with a high risk of overdose – even in small quantities. Nutriband (NASDAQ: NTRB) is advancing its AVERSA(TM) technology that features aversive agents to prevent abuse, diversion, misuse, and accidental exposure to drugs with abuse potential, specifically opioids.
“AVERSA is a platform technology that can be deployed in almost any transdermal product that carries a risk of abuse or misuse. It is our mission to reduce the risk profile of these drugs while ensuring availability for patients that need them,” said NTRB CEO Gareth Sheridan in recent statements (https://nnw.fm/XGpAs ).
The abuse of fentanyl is contributing to the worst drug crisis in the history of the United States. According to the Council on Foreign Relations, more than a million people in the United States have died of drug overdoses since 2000, and the majority of these cases were due to opioids with fentanyl being the leading cause (https://nnw.fm/s3oiA ). In the last two years alone, overdose rates have been approximately 112,000 and 108,000 respectively.
Despite its potential for abuse, fentanyl has legitimate medical uses when prescribed and administered properly to treat chronic pain. Used commonly in medical settings, the drug effectively manages post-operative pain, cancer-related pain, and pain associated with severe injuries. Additionally, it is sometimes used as anesthesia during surgical procedures due to its fast-acting and short-duration properties.
NTRB is facilitating the responsible use of fentanyl through its AVERSA(TM) technology. AVERSA(TM) works by incorporating aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. By incorporating these aversive agents onto the backing of the patch, AVERSA(TM) aims to deter individuals from tampering with or abusing the medication while ensuring the medication remains accessible to patients who genuinely need it for pain management. The Company is partnered with Kindeva Drug Delivery, utilizing Kindeva’s FDA approved Fentanyl patch and adding Nutriband’s AVERSA technology. The Company aims to file for FDA marketing approval in 2025.
Nutriband recently announced the issuance of a new U.S. patent No. 11,759,431 for its AVERSA(TM) abuse deterrent technology by the United States Patent and Trademark Office (https://nnw.fm/jjBHe ). This patent expands Nutriband’s intellectual property protection in the United States for its portfolio of abuse deterrent transdermal products.
“The issuance of this patent covering our AVERSA(TM) abuse deterrent transdermal technology that utilizes taste aversion to address a primary route of abuse of opioid patches is an important component of our global IP portfolio,” said CEO Gareth Sheridan.
“This new patent strengthens our intellectual property position, which includes patents issued in 45 countries around the world.”
Nutriband Inc. primarily engages in developing its portfolio of transdermal pharmaceutical products. Led by an experienced management team with extensive experience in the pharmaceutical sector, the company is dedicated to its mission of enhancing the safety, efficacy, and responsible use of pharmaceutical treatments for patients worldwide.
For more information, visit the company’s website at www.Nutriband.com.
NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://nnw.fm/NTRB
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
- Fentanyl is a potent opioid that is associated with a significant risk of abuse and overdose, contributing to a major drug crisis in the United States
- Fentanyl has legitimate medical uses in managing severe and chronic pain in medical settings such as hospitals and surgical procedures
- NTRB is advancing its AVERSA(TM) technology that incorporates aversive agents to prevent abuse, diversion, misuse, and accidental exposure to opioids and other drugs with abuse potential
- NTRB was recently granted a patent for AVERSA(TM), strengthening its intellectual property portfolio in the United States and globally across 45 countries
Fentanyl, a potent opioid, poses a significant problem due to its potential for abuse with a high risk of overdose – even in small quantities. Nutriband (NASDAQ: NTRB) is advancing its AVERSA(TM) technology that features aversive agents to prevent abuse, diversion, misuse, and accidental exposure to drugs with abuse potential, specifically opioids.
“AVERSA is a platform technology that can be deployed in almost any transdermal product that carries a risk of abuse or misuse. It is our mission to reduce the risk profile of these drugs while ensuring availability for patients that need them,” said NTRB CEO Gareth Sheridan in recent statements (https://nnw.fm/XGpAs ).
The abuse of fentanyl is contributing to the worst drug crisis in the history of the United States. According to the Council on Foreign Relations, more than a million people in the United States have died of drug overdoses since 2000, and the majority of these cases were due to opioids with fentanyl being the leading cause (https://nnw.fm/s3oiA ). In the last two years alone, overdose rates have been approximately 112,000 and 108,000 respectively.
Despite its potential for abuse, fentanyl has legitimate medical uses when prescribed and administered properly to treat chronic pain. Used commonly in medical settings, the drug effectively manages post-operative pain, cancer-related pain, and pain associated with severe injuries. Additionally, it is sometimes used as anesthesia during surgical procedures due to its fast-acting and short-duration properties.
NTRB is facilitating the responsible use of fentanyl through its AVERSA(TM) technology. AVERSA(TM) works by incorporating aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. By incorporating these aversive agents onto the backing of the patch, AVERSA(TM) aims to deter individuals from tampering with or abusing the medication while ensuring the medication remains accessible to patients who genuinely need it for pain management. The Company is partnered with Kindeva Drug Delivery, utilizing Kindeva’s FDA approved Fentanyl patch and adding Nutriband’s AVERSA technology. The Company aims to file for FDA marketing approval in 2025.
Nutriband recently announced the issuance of a new U.S. patent No. 11,759,431 for its AVERSA(TM) abuse deterrent technology by the United States Patent and Trademark Office (https://nnw.fm/jjBHe ). This patent expands Nutriband’s intellectual property protection in the United States for its portfolio of abuse deterrent transdermal products.
“The issuance of this patent covering our AVERSA(TM) abuse deterrent transdermal technology that utilizes taste aversion to address a primary route of abuse of opioid patches is an important component of our global IP portfolio,” said CEO Gareth Sheridan.
“This new patent strengthens our intellectual property position, which includes patents issued in 45 countries around the world.”
Nutriband Inc. primarily engages in developing its portfolio of transdermal pharmaceutical products. Led by an experienced management team with extensive experience in the pharmaceutical sector, the company is dedicated to its mission of enhancing the safety, efficacy, and responsible use of pharmaceutical treatments for patients worldwide.
For more information, visit the company’s website at www.Nutriband.com.
NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://nnw.fm/NTRB
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
